New Integrase Inhibitors RAL, EVG and DTG improving the efficacy of ARVs in controlling HIV replication by providing personalized therapy.
Continue readingStudy: New HIV Integrase Inhibitors RAL, EVG and DTG
Posts Tagged → #raltegravir
HIV PEP drugs: Truvada® combination therapy
Truvada® is commonly used in combination with Isentress® for PEP due to the effectiveness and lack of negative interaction between the two drugs. Learn more in this detailed guide.
Continue readingHIV PEP drugs: Isentress® (Raltegravir) intergrase inhibitor
Isentress® is one of the newest classes of antiretrovirals, the intergrase inhibitors. This drug disables the HIV intergrase protein which is responsible for integrating the viral genome into the human chromosome and causing the chronic incurable infection. Developed by Merck and Co, it was approved for adult use in 2007 by the FDA and use… Continue reading
The World of Antiretrovirals
In the 1980’s diagnosis with HIV was a death sentence. In 1995 in the USA, it was the highest cause of death in the age range 25-44 years. Nowadays HIV is a life sentence, but a relatively painless one. Anti-retroviral therapy (ART) has ensured that the virus is kept locked away in the host DNA,… Continue reading
New York State Department of Health AIDS Institute recently updated their HIV PEP guidelines
The New York State Department of Health AIDS Institute (NYSDHAI) recently tasked their Medical Care Criteria Committee (MCCC) to update their HIV PEP (Post-exposure Prophylaxis) guidelines. PEP refers to the treatment required and administered after exposure to HIV – a sexually transmitted disease (STD). This exposure is categorised as resulting from sexual assault, occupational exposure,… Continue reading